Research Progress on Molecular Mechanisms of Tumor Budding in Colorectal Cancer

² Key Laboratory of Molecular Pathology and Early Diagnosis of Tumor in Hebei Province; Pathology Department of Baoding First Central Hospital of Hebei Province, Hebei Province, China,

³ Key Laboratory of Molecular Pathology and Early Diagnosis of Tumor in Hebei Province; Pathology Department of Baoding First Central Hospital of Hebei Province, Hebei Province, China,

PAR 2021 , 5(4), 70–76; https://doi.org/10.26689/par.v5i4.2340

© 2021 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Abstract

Tumor buds are usually defined as isolated single cancer cells or clusters of up to four cancer cells located at the front of invasive tumors which play an important role in the clinical pathological study of colorectal cancer. The prognostic value of tumor budding in colorectal cancer has been supported by a large amount of evidence. However, its molecular mechanism remains unclear, and it is also a research hotspot now. This paper reviews the latest research progress on the molecular mechanisms of tumor budding in colorectal cancer.

References

Bosman FT, Carneiro F, Hruban RH, et al., 2010, WHO Classification of Tumours of the Digestive System, Fourth Edition. International Agency for Research on Cancer (IARC), Lyon.

Arnold M, Sierra MS, Laversanne M, et al., Global Patterns and Trends in Colorectal Cancer Incidence and Mortality. Gut, 2017, 66(4): 683-691.

De Smedt L, Palmans S, Sagaert X, 2016, Tumour Budding in Colorectal Cancer: What Do We Know and What can We Do?. Virchows Arch, 468(4): 397-408.

Lugli A, Karamitopoulou E, Zlobec I, 2012, Tumour Budding: A Promising Parameter in Colorectal Cancer. Br J Cancer, 106(11): 1713-1717.

Zhou B, Zong S, Zhong W, et al., 2020, Interaction Between Laminin-5?2 and Integrin ?1 Promotes the Tumor Budding of Colorectal Cancer via the Activation of Yes-Associated Proteins. Oncogene, 39(7): 1527-1542.

Yurchenco PD, McKee KK, Reinhard JR, et al., 2018, Laminin-Deficient Muscular Dystrophy: Molecular Pathogenesis and Structural Repair Strategies. Matrix Biol, 71-72: 174-187.

Nishiuchi R, Takagi J, Hayashi M, et al., 2006, Ligand-Binding Specificities of Laminin-Binding Integrins: A Comprehensive Survey of Laminin–Integrin Interactions Using Recombinant ?3?1, ?6?1, ?7?1 and ?6?4 Integrins. Matrix Biol, 25: 189-197.

Moon YW, Rao G, Kim JJ, et al., 2015, LAMC2 Enhances the Metastatic Potential of Lung Adenocarcinoma. Cell Death Differ, 22: 1341–1352.

Kalluri R, Weinberg RA, 2009, The Basics of Epithelial-Mesenchymal Transition. J Clin Investig, 119: 1420–1428.

Shen J, Cao B, Wang Y, et al., 2018, Hippo Component YAP Promotes Focal Adhesion and Tumour Aggressiveness via Transcriptionally Activating THBS1/FAK Signalling in Breast Cancer. J Exp Clin Cancer Res, 37: 175.

Tomasetto C, Moog-Lutz C, Regnier CH, et al., 1995, Lasp-1 (MLN 50) Defines a New LIM Protein Subfamily Characterized by the Association of LIM and SH3 Domains. FEBS Lett, 373: 245-249.

Zhao L, Wang H, Liu C, et al., 2010, Promotion of Colorectal Cancer Growth and Metastasis by the LIM and SH3 Domain Protein 1. Gut, 59: 1226–1235.

Wang H, Shi J, Luo Y, et al., LIM and SH3 Protein 1 Induces TGFbeta-Mediated Epithelial-Mesenchymal Transition in Human Colorectal Cancer by Regulating S100A4 Expression. Clin Cancer Res, 2014, 20: 5835–5847.

Yan P, Liu J, Zhou R, et al., 2020, LASP1 Interacts with N-WASP to Activate the Arp2/3 Complex and Facilitate Colorectal Cancer Metastasis by Increasing Tumour Budding and Worsening the Pattern of Invasion. Oncogene, 39(35): 5743-5755.

Lane J, Martin T, Weeks HP, et al., 2014, Structure and Role of WASP and WAVE in Rho GTPase Signalling in Cancer. Cancer Genom Proteom, 11: 155–165.

Caie PD, Turnbull AK, Farrington SM, et al., 2014, Quantification of Tumour Budding, Lymphatic Vessel Density and Invasion Through Image Analysis in Colorectal Cancer. J Transl Med, 12: 156.

Bresnick AR, Weber DJ, Zimmer DB, 2015, S100 Proteins in Cancer. Nat Rev Cancer, 15: 96–109.

Tantyo NA, Karyadi AS, Rasman SZ, et al., 2019, The Prognostic Value of S100A10 Expression in Cancer. Oncol Lett, 17: 1417–1424.

Li C, Ma Y, Fei F, et al., 2020, Critical Role and Its Underlying Molecular Events of the Plasminogen Receptor, S100A10 in Malignant Tumor and Non-Tumor Diseases. J Cancer, 11: 826–836.

Bydoun M, Sterea A, Weaver ICG, et al., 2018, A Novel Mechanism of Plasminogen Activation in Epithelial and Mesenchymal Cells. Sci Rep, 8: 1–17.

Fei F, Liu K, Li C, et al., 2020, Molecular Mechanisms by Which S100A4 Regulates the Migration and Invasion of PGCCs with Their Daughter Cells in Human Colorectal Cancer. Front Oncol, 10: 1–13.

Zhang S, Zhang D, Yang Z, et al., 2016, Tumor Budding, Micropapillary Pattern, and Polyploidy Giant Cancer Cells in Colorectal Cancer: Current Status and Future Prospects. Stem Cells Int, 2016: 4810734.

Arai K, Iwasaki T, Sonoda A, et al., 2020, Membranous Overexpression of S100A10 is Associated with a High-Grade Cellular Status of Breast Carcinoma. Med Mol Morphol, 53: 104–114.

Arai K, Iwasaki T, Tsuchiya C, et al., 2020, Annexin A2 expression in the Aerogenous Spread of Pulmonary Invasive Mucinous Adenocarcinoma with Gastric Lineage. Case Rep Oncol Med, 2020:2492636.

Tristante E, Martinez CM, Jimenez S, et al., 2015, Association of a Characteristic Membrane Pattern of Annexin A2 with High Invasiveness and Nodal Status Colon Adenocarcinoma. Transl Res, 166: 196–206.

Arai K, Ishimatsu H, Iwasaki T, et al., 2020, Membranous S100A10 Involvement in the Tumor Budding of Colorectal Cancer During Oncogenesis: Report of Two Cases with Immunohistochemical Analysis. World J Surg Oncol, 18(1): 289.

Najafi M, Farhood B, Mortezaee K, et al., 2020, Hypoxia in Solid Tumors: A Key Promoter of Cancer Stem Cell (CSC) Resistance. J Cancer Res Clin Oncol, 146(1): 19-31.

Ziskin JL, Dunlap D, Yaylaoglu M, et al., 2013, In Situ Validation of An Intestinal Stem Cell Signature in Colorectal Cancer. Gut, 62: 1012–1023.

He S, Zhou H, Zhu X, et al., 2014, Expression of Lgr5, a Marker of Intestinal Stem Cells, in Colorectal Cancer and its Clinicopathological Significance. Biomed Pharmacother, 68: 507–513.

Konishi T, Shimada Y, Lee LH, et al., 2018, Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers. Am J Surg Pathol, 42: 705–714.

Sato K, Uehara T, Iwaya M, et al., 2020, Correlation of Clinicopathological Features and LGR5 Expression in Colon Adenocarcinoma. Annals of Diagnostic Pathology, 48: 151587.

Idos GE, Kwok J, Bonthala N, et al., 2020, The Prognostic Implications of Tumor Infiltrating Lymphocytes in Colorectal Cancer: A Systematic Review and Meta-Analysis. Sci Rep, 10: 3360.

Cole LA, 2012, HCG, the Wonder of Today’s Science. Reprod Biol Endocrinol, 10: 24.

Lundin M, Nordling S, Lundin J, et al., 2001, Tissue Expression of Human Chorionic Gonadotropin Beta Predicts Outcome in Colorectal Cancer: A Comparison with Serum Expression. Int J Cancer, 95(1): 18-22.

De Smedt L, Palmans S, Andel D, et al., 2017, Expression Profiling of Budding Cells in Colorectal Cancer Reveals an EMT-Like Phenotype and Molecular Subtype Switching. Br J Cancer, 116(1): 58-65.

Berndt S, Blacher S, Munaut C, et al., 2013, Hyperglycosylated Human Chorionic Gonadotropin Stimulates Angiogenesis Through TGF-Beta Receptor Activation. FASEB J, 27(4): 1309–1321.

Gulubova M, Manolova I, Ananiev J, et al., 2010, Role of TGF-beta1, its Receptor TGFbetaRII, and Smad Proteins in the Progression of Colorectal Cancer. Int J Colorectal Dis, 25(5): 591–599.

Zlobec I, Molinari F, Martin V, et al., 2010, Tumor Budding Predicts Response to Anti-EGFR Therapies in Metastatic Colorectal Cancer Patients. World J Gastroenterol, 16(38): 4823-4831.

Moulton HM, Yoshihara PH, Mason DH, et al., 2002, Active Specific Immunotherapy with a Beta-Human Chorionic Gonadotropin Peptide Vaccine in Patients with Metastatic Colorectal Cancer: Antibody Response is Associated with Improved Survival. Clin Cancer Res, 8(7): 2044–2051.

Previous article in this issue

Next article in this issue